TG Therapeutics (TGTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained a Buy rating on the stock and has a $50.00 price target.
Tara Bancroft’s rating is based on TG Therapeutics’ impressive financial performance and strategic advancements. The company reported a significant increase in its US net Briumvi revenue, surpassing expectations with an 11% quarter-over-quarter growth and a $5 million beat on guidance. This robust revenue performance is attributed to both new and repeat prescriptions, indicating strong market acceptance and prescriber confidence in Briumvi.
Tara Bancroft also considers the company’s optimistic outlook and strategic initiatives as key factors for the Buy rating. TG Therapeutics has raised its revenue guidance for 2025, projecting substantial growth. Additionally, the expansion of Briumvi’s availability in Europe and other regions is expected to contribute to future revenue streams. These factors collectively suggest a promising growth trajectory for TG Therapeutics, justifying the Buy recommendation.